FDA Finds IDM Pharma’s Junovan Study Lacking
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee meets May 9 to review the osteosarcoma therapy.
You may also be interested in...
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Takeda is gearing up for a 2010 launch of the orphan bone cancer immunotherapy Mepact (mifamurtide) in Europe and is considering re-submitting its failed U.S. FDA application for that compound, after buying IDM Pharma for $75 million in a deal announced May 18
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.